Advertisement

Der Einfluß von Motilitäts- und Adhäsionsfaktoren auf die Differenzierung und Invasivität des Harnblasenkarzinoms

  • T. Otto
  • H. Rübben
Conference paper

Zusammenfassung

Das Harnblasenkarzinom ist neben dem Prostatakarzinom der häufigste maligne urologische Tumor. Männer erkranken etwa 3mal so häufig wie Frauen, das bevorzugte Erkrankungsalter liegt zwischen dem 50. und 70. Lebensjahr; die Inzidenz beträgt 20 Neuerkrankungen/100.000 Einwohner/Jahr. Mehr als 60% aller Blasentumoren wachsen oberflächlich, d.h. sind zum Zeitpunkt der Diagnosestellung noch nicht in die Blasenwandmus-kulatur infiltriert. Bis vor wenigen Jahren glaubte man, daß das oberflächliche Harnblasenkarzinom hinsichtlich der Prognose eine homogene Gruppe darstellt. Dies wird jedoch der Biologie des oberflächlichen Blasenkarzinoms nicht gerecht. Bereits eine oberflächliche Infiltration in die Lamina propria sowie eine Entdifferenzierung des Tumors beeinflussen die Prognose der Patienten ungünstig; d. h. alleine die beiden Faktoren Infiltrationstiefe und Differenzierungsgrad lassen prognostisch sehr unterschiedliche Patientengruppen erkennen: Patienten mit fehlender Infiltration (Stadium Ta) weisen eine 5-Jahres-Überlebensrate von 95% auf, während Patienten mit einem Tumor, der in die Lamina propria infiltriert ist und einen schlechten Differenzierungsgrad aufweist (Stadium Tl G3) nur noch in 64% 5 Jahre überleben. Die ungünstige Prognose der Patienten mit Tl-G3-Tumoren ist sowohl durch eine lokale Tumorprogression als auch durch eine primäre Fernmetastasierung bestimmt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. AMERICAN CANCER SOCIETY (1992) Cancer Facts and Figures 1992: 27 Barnes R, Hirst A, Rosenquist R (1976) Early carcinoma of the prostate: comparison of stages A and B. J Urol 115: 404Google Scholar
  2. Bartsch G, Hohlbrugger G, Mikuz G, Marberger H (1983) Transurethral resection in prostatic carcinoma. A cause of accelerated metastatic growth. World J Urol 1: 36CrossRefGoogle Scholar
  3. Behrens J, Birchmeier W (1990) Specific activity of the arc-1/uvomorulin promoter in epithelial cells. J Cell Biol 111: 157aGoogle Scholar
  4. Behrens J, Birchmeier W, Goodman SL, Imhof BA (1985) Dissociation of madin-darby canine kidney epithelial cells by the monoclonal antibody anti-arc-1: Mechanistic aspects and identification of the antigen as a component related to uvomorulin. J Cell Biol 1001: 1307CrossRefGoogle Scholar
  5. Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting tumor cells invasion: Epithelial cells acquire invasive properties after loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108: 2435PubMedCrossRefGoogle Scholar
  6. Bussemakers MJG, Van Mooreselaar RJA, Giroldi LA et al. (in press) Decreased expression of E-Cadherin in the progression of rat prostatic cancer. Cancer Res (in press)Google Scholar
  7. Carter BS, Ewing CM, Ward WS et al. (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci 87: 8751PubMedCrossRefGoogle Scholar
  8. Chlewbowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide (NSC 26 271) versus the combination of adriamycin (NSC 123 127), 5-fluorouracil (NSC 19 893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial. Cancer 42: 2546CrossRefGoogle Scholar
  9. Correa RJ Jr, Anderson RG, Gibbons RP, Mason JT (1974) Latent carcinoma of the prostate — why the controversy. J Urol 111: 644PubMedGoogle Scholar
  10. Eagan RT, Hahn RG, Myers RP (1996) Adriamycin (NSC 127 127) versus 5-fluorouracil (NSC 19 893) and cyclophosphamid (NSC 26 271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60: 115Google Scholar
  11. Eidelman S, Damsky CH, Wheelock MJ, Damjanov I (1989) Expression of the cell-cell adhesion glycoprotein cell-CAM 120/80 in normal human tissue and tumor. Am J Pathol 135: 101PubMedGoogle Scholar
  12. Frixen UH, Behrens J, Sacks M et al. (1991) E-Cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173PubMedCrossRefGoogle Scholar
  13. Greene LF, Simon HB (1955) Occult carcinoma of the prostate. Clinical and therapeutic study of eighty-three cases. JAMA 158: 1494Google Scholar
  14. Guirguis R (1988) Detection of autocrine motility factor in urine as a marker of bladder cancer. J Natl Cancer Inst 80/15: 1203PubMedGoogle Scholar
  15. Hermanek P (1986) Neue TNM/pTNM-Klassifikation und Stadieneinteilung urologischer Tumoren ab 1987. Urologe (B) 26/4: 193Google Scholar
  16. Khalifa NM, Jarman WB (1976) A study of 48 cases of incidental carcinoma of the prostate. Followed 10 years or longer. J Urol 116: 329PubMedGoogle Scholar
  17. Liotta LA (1986) Tumor cell autocrine motility factor. Proc Natl Acad Sci 83/10: 3302PubMedCrossRefGoogle Scholar
  18. Muss HB, Howard V, Richards F et al. (1981) Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer — a randomized trial. Cancer 47: 1949PubMedCrossRefGoogle Scholar
  19. Nabi IR, Watanabe H, Raz A (1990) Identification of B16-F1 melanoma autocrine motility — like factor receptor. Cancer Res 50: 409PubMedGoogle Scholar
  20. Nabi IR, Watanabe H, Silletti S, Raz A (1991) Tumor cell autocrine motility factor receptor. In: Goldberg ID (ed) Cell motility factors. Birkhäuser, Basel, p 164Google Scholar
  21. Nagafuchi A, Shirayoshi Y, Okazaki K, Yasuda K, Takeichi M (1987) Transformation of cell adhesion properties by exogenously introduced E-Cadherin cDNA. Nature 329: 341PubMedCrossRefGoogle Scholar
  22. Paulson DF (1987) Management of prostatic malignancy. In: DeKernion JB, Paulson DF (eds) Genitourinary cancer management. Lea & Febiger, Philadelphia, p 107Google Scholar
  23. Rübben H, Altwein JE (1987) Das Prostatakarzinom — ein therapeutisches Dilemma? Urologe (A) 26: 7Google Scholar
  24. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, Nakamura Y (1990) Allelotype of breast cancer: cumulative losses promote tumor progresion in primary breast cancer. Cancer Res 50: 7184PubMedGoogle Scholar
  25. Schalken JA, Bussemakers MJG, Isaacs WB, Carter BS, Van de Veen WJM, Debruyne FMJ (1991) E-Cadherin is a candidate tumor suppressor gene implicated in prostate cancer. Societe International D’Urologie, 22th Congress 425: 352Google Scholar
  26. Sheldon CA, Williams RD, Fraley EE (1980) Incidental carcinoma of the prostate: a review of literature and critical reappraisal of classification. J Urol 124Google Scholar
  27. Shimoyama Y, Hirohashi S, Hirano S, Noguchi M, Shimosato Y, Takeichi M, Abe O (1980) Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res 49: 2128Google Scholar
  28. Soloway MS, DeKernion JB, Gibbons RP et al. (1981) Comparison of estramustine phosphate and vincristin alone or in combination for patients with advanced hormone refractory previously irradiated carcinoma of the prostate. J Urol 125: 664PubMedGoogle Scholar
  29. Stamey TA, Kabalin IN (1989) Prostate specific antigen in diagnosis and treatment of adenocarcinoma of the prostate. J Urol 141: 1070PubMedGoogle Scholar
  30. Stoker M, Gherardi E, Perryman M, Gray J (1987) Scatter factor is a fibsoblast-derived modulator of epithelial cell motility. J Nature 327: 239CrossRefGoogle Scholar
  31. Stracke ML, Guirguis R, Liotta LA, Schiffmann E (1987) Pertussis toxin inhibits stimulated motility indipendently of the adenylate cyclase pathway in human melanoma cells. Biochem Biophys Res Comm 146/1: 339PubMedCrossRefGoogle Scholar
  32. Tsuda H, Zhang W, Shimosato Y et al. (1990) Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6791PubMedCrossRefGoogle Scholar
  33. Umbas R, Bussemakers MJG, Isaacs WB, Aalders TW, Carter BS, Debruyne FMJ, Schalken JA (in press) Decreased expression of E-Cadherin in high grade prostate cancer. Cancer Res (in press)Google Scholar
  34. De Voogt H, Sucin S, Sylvester R, Pavone-Macaluso M, Smith PH, De Pauw M (1989) Multivariante analysis of prognostik factors in patients with advanced prostatic cancer: results from 2 european organization for research on treatment of cancer trials. J Urol 141: 883PubMedGoogle Scholar
  35. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W (1990) Scatterfactor: Molecular characteristics and effect on the invasion of epithelial cells. J Cell Biol IE: 2097Google Scholar
  36. Yagoda A (1979) Phase II trials with cis-diammine-dichloroplantinum (II) in the treatment of urothelial tumors. Cancer Treat Rep 63: 1565PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • T. Otto
  • H. Rübben

There are no affiliations available

Personalised recommendations